CA3074406A1 - Bacteriophage for modulating inflammatory bowel disease - Google Patents

Bacteriophage for modulating inflammatory bowel disease Download PDF

Info

Publication number
CA3074406A1
CA3074406A1 CA3074406A CA3074406A CA3074406A1 CA 3074406 A1 CA3074406 A1 CA 3074406A1 CA 3074406 A CA3074406 A CA 3074406A CA 3074406 A CA3074406 A CA 3074406A CA 3074406 A1 CA3074406 A1 CA 3074406A1
Authority
CA
Canada
Prior art keywords
bacteriophage
kp2w
kp2m
kp3w
mkp2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3074406A
Other languages
English (en)
French (fr)
Inventor
Kenya Honda
Koji Atarashi
Seiko Narushima
Eran Elinav
Rotem Sorek
Efrat Khabra
Hava Ben David
Eyal Weinstock
Sarah Pollock
Yulia Mutiuhin
Naomi Zak
Original Assignee
Yeda Research And Development Co Ltd At Weizmann Institute Of Scie
Biomx Ltd
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co Ltd At Weizmann Institute Of Scie, Biomx Ltd, Keio University filed Critical Yeda Research And Development Co Ltd At Weizmann Institute Of Scie
Publication of CA3074406A1 publication Critical patent/CA3074406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3074406A 2017-09-08 2018-09-07 Bacteriophage for modulating inflammatory bowel disease Abandoned CA3074406A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555790P 2017-09-08 2017-09-08
US62/555,790 2017-09-08
PCT/IB2018/001128 WO2019048930A2 (en) 2017-09-08 2018-09-07 BACTERIOPHAGE OF MODULATION OF INFLAMMATORY INTESTINAL DISEASE

Publications (1)

Publication Number Publication Date
CA3074406A1 true CA3074406A1 (en) 2019-03-14

Family

ID=64316588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3074406A Abandoned CA3074406A1 (en) 2017-09-08 2018-09-07 Bacteriophage for modulating inflammatory bowel disease

Country Status (7)

Country Link
US (1) US20220031776A1 (https=)
EP (2) EP4032526A1 (https=)
JP (1) JP2020533408A (https=)
CN (1) CN111801107A (https=)
AU (1) AU2018330848A1 (https=)
CA (1) CA3074406A1 (https=)
WO (1) WO2019048930A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods
CN112469426B (zh) * 2018-05-23 2025-07-11 布莱阿姆青年大学 噬菌体组合物和试剂盒及相关方法
EP3934672A1 (en) * 2019-03-07 2022-01-12 Keio University Bacteriophage for modulating inflammatory bowel disease
US20240075084A1 (en) * 2021-01-21 2024-03-07 Biomx Ltd. Klebsiella bacteriophage and uses thereof
IL307852A (en) * 2021-04-22 2023-12-01 Ferring Bv Bacteriophage therapy against adherent-invasive escherichia coli
CN115558650B (zh) * 2022-10-09 2023-05-30 优宜邦生物科技(上海)有限公司 一种宽宿主谱变栖克雷伯氏菌噬菌体及其应用和制剂
CN118318913A (zh) * 2024-05-09 2024-07-12 江苏省农业科学院 一种含有噬菌体的新型饲料添加剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP2799063A1 (en) * 2013-04-30 2014-11-05 Ferring B.V. Bacteriophage therapy
CN106754745B (zh) * 2016-11-29 2020-07-14 江苏省农业科学院 一种肺炎克雷伯氏菌噬菌体及其应用

Also Published As

Publication number Publication date
AU2018330848A1 (en) 2020-03-12
US20220031776A1 (en) 2022-02-03
WO2019048930A3 (en) 2019-04-18
JP2020533408A (ja) 2020-11-19
EP3678639A2 (en) 2020-07-15
EP3678639B1 (en) 2022-02-16
EP4032526A1 (en) 2022-07-27
WO2019048930A2 (en) 2019-03-14
CN111801107A (zh) 2020-10-20

Similar Documents

Publication Publication Date Title
EP3678639B1 (en) Bacteriophage for modulating inflammatory bowel disease
AU2021215181B2 (en) Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
US12390499B2 (en) Bacteriophage for modulating inflammatory bowel disease
US12011466B2 (en) Modified Escherichia coli strain Nissle and treatment of gastrointestinal disorder
EP4355345A1 (en) Bacteriophages against vancomycin-resistant enterococci
WO2019191508A1 (en) Biomarker and treatment target for alcoholic hepatitis
CN118374460A (zh) 一种铜绿假单胞菌噬菌体及其应用
US20220387525A1 (en) Compositions and methods for microbiome modulation
WO2021231689A1 (en) Phage-mediated delivery of genes to gut microbiome
Awad et al. LicD-mediated cell wall decoration governs phage sensitivity in Enterococcus faecalis clinical isolates
Brzozowski et al. A prophage-encoded sRNA limits lytic phage infection of adherent-invasive E. coli
RU2717435C1 (ru) Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов
KR20260013472A (ko) 알콜-연관 간염에 대한 파지 요법
Fitzgerald et al. A comparative analysis of the genus Faecalibacterium and the utilisation of an enrichment based strategy for the isolation of gut phage
Ely Mobile Genetic Elements of Enterococcus faecalis in the Murine Intestine
WO2021084111A2 (en) Coliphages and uses thereof
DUBEY ISOLATION AND CHARACTERIZATION OF LYTIC PHAGES TO REDUCE THE RISK OF Vibrio parahaemolyticus INFECTION IN AQUACULTURE ENVIRONMENT
CA3217216A1 (en) Bacteriophage therapy against adherent-invasive escherichia coli
CN119970803A (zh) 芽植菌属细菌在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240307